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A B S T R A C T
Accurate detection and quantiﬁcation of microbiological contaminations remains an issue mainly due the
lack of rapid and precise analytical techniques. Standard methods are expensive and time-consuming
being associated to high economic losses and public health threats. In the context of pharmaceutical
industry, the development of fast analytical techniques able to overcome these limitations is crucial and
spectroscopic techniques might constitute a reliable alternative. In this work we proved the ability of
Fourier transform near infrared spectroscopy (FT-NIRS) to detect and quantify bacteria (Bacillus subtilis,
Escherichia coli, Pseudomonas ﬂuorescens, Salmonella enterica, Staphylococcus epidermidis) from 10 to
108 CFUs/mL in sterile saline solutions (NaCl 0.9%). Partial least squares discriminant analysis (PLSDA)
models showed that FT-NIRS was able to discriminate between sterile and contaminated solutions for all
bacteria as well as to identify the contaminant bacteria. Partial least squares (PLS) models allowed
bacterial quantiﬁcation with limits of detection ranging from 5.1 to 9 CFU/mL for E. coli and B. subtilis,
respectively. This methodology was successfully validated in three pharmaceutical preparations (contact
lens solution, cough syrup and topic anti-inﬂammatory solution) proving that this technique possess a
high potential to be routinely used for the detection and quantiﬁcation of bacterial contaminations.
ã 2015 Elsevier B.V. All rights reserved.
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Pharmaceuticals are widely used in a variety of ways in the
prevention, treatment, and diagnosis of diseases. Although sterility
is not a requirement in ofﬁcial compendia for non-sterile
pharmaceuticals, bioburdens need to be within acceptable limits
(Hugo and Russell, 1998). Accordingly with the European
Pharmacopeia (European Pharmacopoeia, 2015), the presence of
certain microorganisms in non-sterile preparations may have the
potential to reduce or even inactivate the product’s therapeutic
activity and adversely affect patients’ health. Any pharmaceutical
product, whether manufactured in the hospital or industrial
environment, has the potential to be contaminated with micro-
organisms, which may include bacteria, yeasts, or molds. Microbial
contamination may be originated from raw materials, may be
introduced during manufacture or contaminated during storage
and use (Denyer and Baird, 2007). The occurrence of microbial* Corresponding author at: Centro de Engenharia Biológica, Universidade do
Minho, Campus de, Gualtar, 4710-057 Braga, Portugal.
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0378-5173/ã 2015 Elsevier B.V. All rights reserved.contamination has been well documented, and contaminants
range from true pathogens such as Clostridium tetani, to
opportunistic ones like P. aeruginosa (Obuekwe et al., 2000). The
European Pharmacopeia (European Pharmacopoeia, 2015) estab-
lished the acceptance criteria for microbiological quality of non-
sterile pharmaceuticals. These criteria impose the absence of
different microorganisms, as E. coli, Staphylococcus aureus, P.
aeruginosa, B. subtilis and Salmonella spp. and deﬁne limits to
others. Standard methods for the quantiﬁcation and identiﬁcation
of microorganisms in pharmaceuticals include ﬂuorescent labeling
(chemiluminescence) (Kricka, 1998; Roda and Guardigli, 2012),
ATP bioluminescence (Denyer and Baird, 2007), chromatography
and spectrophotometry (Sutton and Cundell, 2004), dye reduction,
electrical resistance, enzyme monitoring (Denyer and Baird, 2007),
Limulus amoebocyte lysate (Hussaini and Hassanali, 1987), nucleic
acid probes (Sutton and Cundell, 2004; Anon., 2000) and phage-
interaction technology (Denyer and Baird, 2007). Some of them are
laborious, time-consuming and/or require expensive equipment
and/or reagents. In this context, the development and implemen-
tation of methods for the identiﬁcation and quantiﬁcation of
bacterial contaminations in pharmaceuticals able to overcome
these limitations are imposed.
200 C. Quintelas et al. / International Journal of Pharmaceutics 492 (2015) 199–206Fourier transform near infrared spectroscopy (FT-NIRS) com-
bined with chemometric methods is frequently chosen for process
analytical technology as to obtain timely measurements of solids,
liquids and other pharmaceutical forms (Bakeev, 2005). It is mainly
used for its speed, low cost and non-destructive characteristics
(Sarraguça and Lopes, 2009). This technique was already used for
the detection and identiﬁcation of bacteria in simple liquid
suspensions (Rodriguez-Saona et al., 2004, 2001). However, and as
far as authors are aware, it was not explored for the identiﬁcation
and quantiﬁcation of bacteria in pharmaceutical products.
The aim of this work was to test the ability of FT-NIRS to detect
and quantify bacterial contaminations in saline solutions (NaCl
0.9%) and pharmaceutical preparations. Five different species
usually responsible for microbial contamination of pharmaceutical
products were used (B. subtilis, E. coli, P. ﬂuorescens, S. enterica, and
S. epidermidis). The methodology was successfully tested in saline
solutions (NaCl 0.9%) and validated in three different pharmaceu-
tical preparations (contact lens solution, cough syrup and topic
anti-inﬂammatory solution).Fig. 1. Score plots of the PLSDA regression models in the spectral range 6000–5400 cm
solutions (NaCl 0.9%) with (a) Bacillus subtilis ( ), (b) Escherichia coli ( ), (c) Pseudomon2. Material and methods
2.1. Contaminated sample solutions
Bacterial isolates used in this work (B. subtilis, E. coli,
P. ﬂuorescens, S. enterica and S. epidermidis) were grown from
frozen stocks in tryptic soy agar (37 C/16 h) prior to the experi-
ments. For each bacterium, a single colony was picked and grown
in tryptic soy broth (37 C/16 h). Bacterial suspension was washed
twice with a saline sterile solution. The pellets were re-suspended
to an OD600 nm= 0.132 and 16 contaminated saline solutions for
each bacterium were prepared through serial dilutions (from 10 to
108 CFU/mL) and used in the proof-of-concept. A sterile saline
solution was used as the negative control.
The pharmaceutical preparations used in this work were
acquired in a local drug store: (a) contact lens solution—sodium
chloride, boric acid, sodium tetraborate, sodium citrate, poloxamer
407, hyaluronic acid, disodium edetate 0.02%, polyhexamethylene
biguanide 0.0001% in puriﬁed water; (b) cough syrup—dextrome-
thorphan 1.8 mg/mL and (3) topic anti-inﬂammatory solution—1 of the discrimination between non-contaminated ( ) and contaminated saline
as ﬂuorescens ( ), (d) Salmonella enterica ( ) and (e) Staphylococcus epidermidis ( ).
Fig. 2. Two perspectives of the scores plot corresponding to the PLSDA regression model in the spectral range 6000–5400 cm1 for the discrimination between saline
solutions (NaCl 0.9%) contaminated with Bacillus subtilis ( ), Escherichia coli ( ), Pseudomonas ﬂuorescens ( ), Salmonella enterica ( ) and Staphylococcus epidermidis ( ).
Table 1
Confusion matrix obtained for the the PLSDA species discrimination model, considering the region 6000–5400 cm1 and 8 LV (values are in%).
FT-NIRS species prediction Species
B. subtilis E. coli P. ﬂuorescens S. enterica S. epidermidis
B. subtilis 20.00 0 0 0.10 0.01 –
E. coli 0 20.00 0 0 0 –
P. ﬂuorescens 0 0 20.00 0 0 –
S. enterica 0 0 0 19.90 0 –
S. epidermidis 0 0 0 0 19.99 –
Sum 20.00 20.00 20.00 19.90 19.99 99.89
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were incubated over-night in tryptic soy broth followed by over-
night incubation in tryptic soy agar to ensure its sterility. A
contaminated saline solution of each bacterium was prepared as
described above and used to contaminate the pharmaceutical
preparations (16 serial dilutions, from 10 to 108 CFU/mL). For each
solution (saline, pharmaceutical and controls) were obtained 10
congruent near-infrared spectra.
2.2. Cell enumeration
The exact number of bacterial cells in each contaminated saline
solution (expressed in CFUs) was determined by using a standard
classical counting method. Brieﬂy, 100 mL of the serial dilutions
were incorporated in plate count agar medium, incubated (37 C,
24 h), and plates containing 30 –300 CFUs were selected for
counting (Buchbinder et al., 1951). This procedure was performed
in the contaminated saline solutions (NaCl 0.9%) used in the proof-
of-concept as well as in the solutions used to contaminate the
pharmaceutical preparations. Details about the exact cellular
concentration (CFU/mL) of each solution were provided in
Table S1 of the Supplementary material.2.3. NIR experiments
Near infrared spectra were recorded on a Fourier-transform
near infrared spectrometer (FTLA 2000, ABB, Thermo Electron
Corporation) equipped with an indium–gallium–arsenide (InGaAs)
detector and connected to a transﬂectance probe (model FLEX-NIR-
12S-300/070504/2, Sapphire Optics) with an optical path length of
2 mm. The probe was connected through optical ﬁbers to the NIR
spectrometer and allowed measurements between 500 and
2500 nm. For each sample, sixty-four scans were made and then
averaged. The integration time was adjusted until the peaks at
1100–1200 nm for NIR were close to 60,000 intensity units. Grams/
AI software (Thermo Electron Corporation) was used for spec-
trometer conﬁguration, control, and data acquisition. The back-
ground was taken every day from an empty probe ensuring that
the probe is dry and cleaned. All solutions were measured by
FT-NIRS at room temperature.
2.4. Data analysis
Near-infrared spectra were pre-processed with Savitzky–Golay
ﬁlter (7 smoothing points, 2nd order polynomial and 2nd
derivative) (Savitzky and Golay, 1964) to remove baseline drifts.
Fig. 3. PLS cross-validation predictions versus experimental contamination levels in saline solutions for the ﬁve analyzed bacteria. Legend: (a) Bacillus subtilis, (b) Escherichia
coli, (c) Pseudomonas ﬂuorescens, (d) Salmonella enterica and (e) Staphylococcus epidermidis.
Table 2
Figures-of-merit of the PLS models developed for the sodium chloride solutions
0.9% (m/v) contaminated with Bacillus subtilis, Escherichia coli, Pseudomonas
ﬂuorescens, Salmonella enterica and Staphylococcus epidermidis.
No. LVs R2 RMSEC RMSECV LOD (Alsberg et al., 1998)
B. subtilis 3 0.961 0.318 1.09 9.0
E. coli 6 0.990 0.0243 0.534 5.1
P. ﬂuorescens 5 0.983 0.0565 0.662 5.7
S. enterica 3 0.970 0.215 0.943 7.8
S. epidermidis 4 0.983 0.120 0.660 5.7
LV: latent variables; R2: correlation coefﬁcient; RMSEC: root mean square error of
the calibration; RMSECV: root mean square error of the cross validation; LOD: limit
of detection (LOD = 3  eRMSECV, CFUs/mL).
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standard normal variate (SNV). Partial least squares (PLS) (Geladi
and Kowalsky,1986) and partial least squares discriminant analysis
(PLSDA) (Barker and Rayens, 2003) were selected to model spectral
data.
PLS regression models were used to estimate contamination
levels (the PLS-1 algorithm was selected). Models were optimized
for the number of latent variables (LVs) considering the leave-one-out cross-validation strategy. Prediction results are analyzed
according to the root-mean-square-error of cross-validation
(RMSECV) that is a measure of the model accuracy. The limit-of-
detection was estimated according Alsberg et al. (1998).
PLSDA is based on the PLS-2 algorithm (Geladi and Kowalsky,
1986; Barker and Rayens, 2003). PLSDA were applied to verify
contamination and for bacteria discrimination purposes. The class
decision criterion for PLSDA results was based on the maximum
value obtained for each predicted class (Barker and Rayens, 2003).
Models are developed on a fraction of the available number of
samples (calibration set—70% of the data) and tested on the
remaining (prediction set—30% of the data). This division is
obtained randomly. The optimal number of latent variables for PLS
is obtained by cross-validation (leave-one-out) using the calibra-
tion set. Discrimination results are expressed in the form of
confusion matrices that compare the real assignment of each
sample with the PLSDA model prediction for prediction set.
Before developing PLS or PLSDA models, datasets are mean-
centred (Geladi and Kowalsky, 1986). All chemometric models
were performed in Matlab version 7.4 Release 2007a (MathWorks,
Natick, MA) and PLS Toolbox version 4.2.1 for Matlab (Eigenvector
Research, Manson, WA).
Fig. 4. Score plots of the PLSDA regression models in the spectral range 6000–
5400 cm1 of the discrimination between (a) cough syrup solutions contaminated
with Escherichia coli ( ) and Salmonella enterica ( ), and (b) topic anti-inﬂammatory
solutions contaminated with Pseudomonas ﬂuorescens ( ) and Staphylococcus
epidermidis ( ).
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3.1. Rationale of the study
This study had a twofold objective: (I) to perform a proof-of-
concept in which we evaluate the ability of FT-NIRS coupled with
chemometrics to detect and quantify bacterial contaminations in
saline solutions (NaCl 0.9%), and (II) to test and validate this
approach in several pharmaceutical preparations. The proof-of-
concept was developed with saline solutions contaminated with
B. subtilis, E. coli, P. ﬂuorescens, S. enterica and S. epidermidis (from
10 to 108 CFUs/mL). Firstly, we evaluated the ability of FT-NIRS to
discriminate sterile from contaminated saline solutions indepen-
dently of their cellular concentration for all the bacterial species
included in this work. We then assess its potential identify the
contaminating bacteria and the cellular concentration of the
contaminated solutions. The developed methodology was then
applied to three pharmaceutical preparations (contact lens
solution, cough syrup and topic anti-inﬂammatory solution) to
evaluate the potential of FT-NIRS to be routinely used as an
alternative method to detect and quantify bacterial contamina-
tions in water base pharmaceutical preparations. All procedures
were repeated in different days to evaluate the reproducibility and
repeatability of the technique.
3.2. Proof-of-concept
Near-infrared spectra obtained from saline solutions (NaCl
0.9%) and pharmaceutical preparations (sterile or contaminated),
present the typical shape of a near-infrared spectra showing large
and broad bands (combinations and overtones) originating from
OH in water. Due to the high water content of all samples, only
the spectral region from 6000 to 5400 cm1 was selected for
chemometric analysis. The rationale is the exclusion of regions
dominated by the absorption bands of water while keeping CH
vibrations of alkanes, alkenes and aromatics.For each bacterium, a partial least squares discriminant analysis
(PLSDA) model was developed to assess the ability of FT-NIRS to
discriminate the non-contaminated saline solution from contami-
nated ones (the entire range of concentrations were considered for
the analysis—please see concentration details in Table S1 of
Supplementary material). A clear discrimination between con-
taminated and non-contaminated solutions was achieved for all
the bacteria included in this study as can be observed by analyzing
the PLSDA model scores in Fig. 1. For all bacteria but one, a two
component model was enough to discriminate solutions with only
a small overlap observed in E. coli. (Fig. 1b). For S. epidermidis a
three-component model was needed for the discrimination.
Additionally, a PLSDA model was developed to evaluate the
discrimination of contaminated saline solutions according to the
contaminant bacteria. The scores plot of the PLSDA model (Fig. 2a
and b showing two different perspectives of the exactly same plot)
clearly showed ﬁve distinct clusters. Each cluster corresponds to
one bacterial species evidencing the ability of this spectroscopic
technique for bacterial discrimination. The confusion matrix of the
PLSDA model considering 8 latent variables (LV) (Table 1) yielded
99.9% of correct predictions being the worst case obtained for
S. enterica with 99.5% of correct predictions. It is of note that
B. subtilis, E. coli and P. ﬂuorescens were always correctly predicted
(100%).
It is noteworthy that both discriminations (between contami-
nated and non-contaminated solutions and according to the
contaminant bacteria) still occur at very low concentrations (about
10 CFU/mL). The exact same procedure was repeated in different
days space by two weeks and comparable results were achieved
(data not shown).
For quantitative purposes, a partial least squares (PLS) model
was developed for each contaminated saline solution considering
samples with concentrations ranging from 10 to 108 CFUs/mL
(Fig. 3a–e). Results are summarized in Table 2. A good correlation
(R2, Table 2) was achieved being the worst case the saline solutions
contaminated with B. subtilis. Both errors, obtained from calibra-
tion (RMSEC) and cross-validation (RMSECV), were found to be
very satisfactory. Moreover, considering the error of cross-
validation and the concentrations range for each bacterium, it
was possible to quantify, with errors lower than 5%: B. subtilis to a
concentration of 73 CFU/mL (4%), E. coli to 85 CFU/mL (2%),
P. ﬂuorescens to 36 CFU/mL (5%), S. enterica to 133 CFU/mL (2%)
and S. epidermidis to 44 CFU/mL (4%). The method’s results yielded
very low limits of detection (LOD). In an independent day, the
quantiﬁcation procedure was repeated for the E. coli contaminated
solutions and analogous results were obtained with a LOD of the
same magnitude and a similar R2 (data not shown).
3.3. Pharmaceutical preparations
We ﬁrstly proved the ability of FT-NIRS to detect and quantify
bacterial contaminations insaline solutions. We furtheraimedtotest
this approach in real pharmaceutical preparations. In this context,
three distinct preparations were selected (contact lens solution,
cough syrup and topic anti-inﬂammatory solution) to strength the
ﬁndings of our study. Similarly to the saline solutions, FT-NIRS was
able to discriminate the non-contaminated pharmaceutical prepa-
rations from the contaminated ones for each bacterium indepen-
dently of its concentration (data not shown). Moreover, it was also
possible to discriminate contaminated cough syrup solutions with E.
coli from those contaminated with S. enterica and the topic anti-
inﬂammatory solutions contaminated with P. ﬂuorescens from those
contaminated with S. epidermidis (Fig. 4a and b, respectively). The
confusion matrix of the PLSDA models yielded a percentage of
correct predictions for species discrimination of 100% for both
solutions (cough syrup and topic anti-inﬂammatory solution).
Fig. 5. PLS cross-validation predictions versus experimental contamination levels in pharmaceutical preparations for the ﬁve analyzed bacteria. Legend: (a) contact lens
solution (Bacillus subtilis); (b) cough syrup (Escherichia coli); (c) cough syrup (Salmonella enterica); (d) anti-inﬂammatory solution (Pseudomonas ﬂuorescens) and (e) anti-
inﬂammatory solution (Staphylococcus epidermidis).
Table 3
Figures-of-merit of the PLS models developed for the pharmaceutical preparations contaminated with Bacillus subtilis, Escherichia coli, Pseudomonas ﬂuorescens, Salmonella
enterica and Staphylococcus epidermidis.
Pharmaceutical preparation Contaminant No. LVs R2 RMSEC RMSECV LOD (Alsberg et al., 1998)
Contact lens solution B. subtilis 4 0.940 0.137 1.05 8.7
Cough syrup E. coli 4 0.952 0.165 1.17 9.6
Cough syrup S. enterica 5 0.917 0.0601 1.10 9.0
Anti-inﬂamatory P. ﬂuorescens 2 0.961 0.568 0.779 6.6
Anti-inﬂammatory S. epidermidis 4 0.943 0.193 1.36 11.7
LV: latent variables; R2: correlation coefﬁcient; RMSEC: root mean square error of the calibration; RMSECV: root mean square error of the cross validation; LOD: limit of
detection (LOD = 3  eRMSECV, CFUs/mL).
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Table 3) it can be seen that it was also possible to quantify the
cellular concentration for each bacteria in the pharmaceutical
preparations with RMSEC and RMSECV very similar to those
obtained for the saline solutions. Also, the LOD obtained was very
satisfactory. In an independent day, a newly contact lens solution
contaminated with B. subtilis was tested and the results obtained for
the PLS model regarding LOD and R2were in accordance with initial
results (data not shown).4. Discussion
In this work we proved the ability of FT-NIRS to detect,
discriminate and quantify microbiological contaminations in saline
solutions (NaCl 0.9%). Moreover, using real pharmaceutical prepa-
rations, we have shown that this infrared based spectroscopic
technique possesses a great potential to be used as an alternative
technique forqualitycontrol in the pharmaceutical industry. FT-NIRS
is a quick, low-cost and environmentally friendly technique with a
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personal making it very attractive for the industry. Several authors
already addressed the potential of FT-NIRS for the pharmaceutical
industry, essentially to monitor solid forms processes. Applications
include the identiﬁcation and quality diagnosis of raw-materials,
active pharmaceutical ingredients and/or excipients quantiﬁcation
and monitoring/control of intermediate solid forms manufacturing
process stages such as blending, granulation, tableting, coating and
packing (Tomuta et al., 2013; Palou et al., 2012; Wahl et al., 2014;
Blanco et al., 2008). Its ability to detect and quantify microbiological
contamination was frequently explored in the context of food
contaminations (Rodriguez-Saona et al., 2004, 2001; Tito et al., 2012)
but barely explored in pharmaceutical contexts. To our knowledge
this is the ﬁrst time that a systematic procedure was tested and
applied in several microorganisms and real pharmaceutical prep-
arations with such promising results. In this study one tested the
bacterial species most often responsible for microbiological
contaminations in the pharmaceutical industry; however, other
species could be detected individually by the same procedure. Also,
the bacterial species select to include in this work possess distinct
characteristics (gram type, coccus, and bacillus, true and opportu-
nistic pathogens) to ensure that the procedure remains feasible
independently of the contaminant bacteria. It is of note that this
methodology could also be used for multiple bacterial species once it
seems to be able to detect whether a solution is or not contaminated
and to quantify the total number of pathogens independently of the
bacterial species present in the solution. However, if the identiﬁca-
tion of the species present in the solution as contaminant is needed
new PLSDA models should be developed and optimized with two or
more pathogens for correct species identiﬁcation. The European
Pharmacopoeia 8.2 (in Microbiological quality of non-sterile
products for pharmaceutical use) establishes the acceptance
criteria for the microbiological quality of non-sterile dosage forms
pointing the tolerable total aerobic microbial count (TAMC)
(European Pharmacopoeia, 2015). In the case of oral aqueous
solutions and cutaneous or nasal preparations, which is the case of
the hereby tested pharmaceutical preparations (except contact lens
solution), the allowed TAMC is 102 CFU/mL (meaning a maximum
acceptable count of 200). Despite the TAMC, for certain pharma-
ceutical preparations, the absence of speciﬁc microorganisms
should be guaranteed. Our results clearly ﬁt the acceptance criteria
established in the European Pharmacopoeia 8.2 stressing the
potential of this spectroscopic technique. Additionally, the repli-
cates performed pointed to the possibility of introducing this
method and comply with reproducibility and repeatability analyti-
cal method criteria. It is of note that FT-NIRS is an infrared-based
spectroscopic technique potentially inﬂuenced by small shifts in
room and samples temperature, being necessary a straight control
of these parameters to ensure the reproducibility and repeatability
of the technique and its validation for routine use.
5. Conclusions
In this work we demonstrate the ability of FT-NIRS to
discriminate non-contaminated from bacteria contaminated saline
solutions considering bacteria most frequently associated with
contaminations in pharmaceutical products. Moreover, we also
proved that this spectroscopic technique can be used to discrimi-
nate the saline solutions according to the contaminant bacteria and
to quantify the extent of the contamination to very low
concentrations. We further validated the method in commonly
used pharmaceutical preparations. Additional work needs to be
done in order to establish accurate calibration procedures to use
this technique as routine; however, the results herein obtained
highlight the potential of this technique as a reliable alternative tobe used in the pharmaceutical industry for the detection and
quantiﬁcation of bacterial contaminations.
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